Have a personal or library account? Click to login
Evaluating plasma and tissue biopsy for DNA methylation markers in early colorectal cancer detection: a systematic review Cover

Evaluating plasma and tissue biopsy for DNA methylation markers in early colorectal cancer detection: a systematic review

Open Access
|Oct 2025

References

  1. World Health Organization. Cancer [Internet]. 2021. [cited 2024 Jan 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
  2. Ibrahim J, Peeters M, Van Camp G, de Beeck KO. Methylation biomarkers for early cancer detection and diagnosis: current and future perspectives. Eur J Cancer. 2023; 178:91–113. doi: 10.1016/j. ejca.2022.10.015
  3. Brenne SS, Madsen PH, Pedersen IS, Hveem K, Skorpen F, Krarup HB, et al. Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study. Br J Cancer. 2023; 129:861–8. doi: 10.1038/s41416-023-02337-4
  4. Malla M, Loree JM, Kasi PM, Parikh AR. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022; 40:2846–57. doi: 10.1200/JCO.21.02615
  5. Hariharan R, Jenkins M. Utility of the methylated SEPT9 test for the early detection of colorectal cancer: a systematic review and meta-analysis of diagnostic test accuracy. BMJ Open Gastroenterol. 2020; 7:e000355. doi: 10.1136/bmjgast-2019-000355
  6. Lima AB, Dos Reis MB, Matsushita M, Dos Reis MT, de Oliveira MA, Reis RM, et al. Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population. Cancer Med. 2023; 12:15854–67. doi: 10.1002/cam4.6224
  7. Yuan RQ, Zhao H, Wang Y, Song K, Yang J, He W, et al. SEPTIN9-SDC2-VIM methylation signature as a biomarker for the early diagnosis of colorectal cancer. Am J Cancer Res. 2022; 12:3128–40. PMID: 35968354
  8. Kassid O, Al-Khikani F, Almosawey H. The evaluation of methylated septin 9 in blood plasma and tissue biopsies for the early detection of asymptomatic colon cancer. Open Access Maced J Med Sci. 2021; 9:1462–9. doi: 10.3889/oamjms.2021.7156
  9. Moreno C, Forero J, Baena Y, Perez L. Co-encapsulation of curcumin and salicylic acid in mucoadhesive polymer nanoparticles. J Appl Pharm Sci. 2024; 14:189-96. doi: 10.7324/JAPS.2024.149645
  10. Nierengarten MB. Colonoscopy remains the gold standard for screening despite recent tarnish: Although a recent study seemed to indicate that colonoscopies are not as effective as once thought at detecting colorectal cancer, a closer look at the study clears the confusion. Cancer. 2023; 129:330–1. doi: 10.1002/cncr.34622
  11. Laugsand EA, Brenne SS, Skorpen F. DNA methylation markers detected in blood, stool, urine, and tissue in colorectal cancer: a systematic review of paired samples. Int J Colorectal Dis. 2021; 36:239–51. doi: 10.1007/s00384-020-03757-x
  12. Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020; 12:eaax7533. doi: 10.1126/scitranslmed.aax7533
  13. US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 325:1965–77. doi: 10.1001/jama.2021.6238
  14. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016; 5:210. doi: 10.1186/s13643-016-0384-4
  15. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155:529–36. doi: 10.7326/0003-4819-155-8-201110180-00009
  16. Zhang X, Wan S, Yu Y, Ruan W, Wang H, Xu L, et al. Identifying potential DNA methylation markers in early-stage colorectal cancer. Genomics. 2020; 112:3365–73. doi: 10.1016/j. ygeno.2020.06.007
  17. Chen Z, Zhao G, Wang K, Wang X, Ma Y, Xiong S, et al. Blood leukocytes methylation levels analysis indicate methylated plasma test is a promising tool for colorectal cancer early detection. J Cancer. 2021; 12:3678–85. doi: 10.7150/jca.57114
  18. Wu X, Zhang Y, Hu T, He X, Zou Y, Deng Q, et al. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. Mol Oncol. 2021; 15:2702–14. doi: 10.1002/18780261.12942
  19. Petit J, Carroll G, Zhao J, Roper E, Pockney P, Scott RJ. Evaluation of epigenetic methylation biomarkers for the detection of colorectal cancer using droplet digital PCR. Sci Rep. 2023; 13:8883. doi: 10.1038/s41598-023-35631-5
  20. Nie Y, Gao X, Cai X, Wu Z, Liang Q, Xu G, et al. Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer. Cancer Commun. 2023; 43:1275–9. doi: 10.1002/cac2.12478
  21. Lei X. Cell-free DNA methylation profiles enable early detection of colorectal and gastric cancer. Am J Cancer Res. 2024; 14:744–61. doi: 10.62347/TPTQ3682
  22. Shavali M, Moradi A, Tahmaseb M, Mohammadian K, Ganji SM. Circulating-tumour DNA methylation of HAND1 gene: a promising biomarker in early detection of colorectal cancer. BMC Med Genomics. 2024; 17:117. doi: 10.1186/s12920-024-01893-9
  23. Baraibar I, Ros J, Saoudi N, Salvà F, García A, Castells MR, et al. Sex and gender perspectives in colorectal cancer. ESMO Open. 2023; 8:101204. doi: 10.1016/j.esmoop.2023.101204
  24. Jamialahmadi K, Azghandi M, Javadmanesh A, Zardadi M, Shams Davodly E, Kerachian MA. A DNA methylation panel for high performance detection of colorectal cancer. Cancer Genet. 2021; 252–253:64–72. doi: 10.1016/j.cancergen.2020.12.007
  25. Winter JM, Uylaki W, Byrne S, Cornthwaite K, Pedersen SK, Roy A, et al. TU1136 hypermethylation of BCAT1 and IKZF1 is an early and persistent event during colorectal carcinogenesis and metastasis. Gastroenterology. 2023; 164:S-991-2. doi: 10.1016/S0016-5085(23)03293-6
  26. Zhao G, Ma Y, Li H, Li S, Zhu Y, Liu X, et al. A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2. Clin Chim Acta. 2020; 503:84–9. doi: 10.1016/j. cca.2020.01.010
  27. Polatoglou E, Mayer Z, Ungerer V, Bronkhorst AJ, Holdenrieder S. Isolation and quantification of plasma cell-free DNA using different manual and automated methods. Diagnostics. 2022; 12:2550. doi: 10.3390/diagnostics12102550
  28. Mojtabanezhad Shariatpanahi A, Rokni P, Shahabi E, Varshoee Tabrizi F, Kerachian MA. Simple and cost-effective laboratory methods to evaluate and validate cell-free DNA isolation. BMC Res Notes. 2018; 11:757. doi: 10.1186/s13104-018-3866-8
  29. Cheli S, Napoli A, Clementi E, Montrasio C. DNA extraction from fresh and frozen plasma: an alternative for real-time PCR genotyping in pharmacogenetics. Mol Biol Rep. 2020; 47:6451–5. doi: 10.1007/s11033-020-05664-4
  30. Bhangu JS, Taghizadeh H, Braunschmid T, Bachleitner-Hofmann T, Mannhalter C. Circulating cell-free DNA in plasma of colorectal cancer patients – a potential biomarker for tumor burden. Surg Oncol. 2017; 26:395–401. doi: 10.1016/j.suronc.2017.08.001
  31. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013; 10:1003–5. doi: 10.1038/nmeth.2633
  32. Buck A, Ly A, Balluff B, Sun N, Gorzolka K, Feuchtinger A, et al. High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples. J Pathol. 2015; 237:123–32. doi: 10.1002/path.4560
  33. Lin Y, Dong ZH, Ye TY, Yang JM, Xie M, Luo JC, et al. Optimization of FFPE preparation and identification of gene attributes associated with RNA degradation. NAR Genom Bioinform. 2024; 6:lqae008. doi: 10.1093/nargab/lqae008
  34. Oliver JA, Ortiz R, Melguizo C, Álvarez PJ, Gómez-Millán J, Prados J. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer. 2014; 14:511. doi: 10.1186/1471-2407-14-511
  35. Centers for Medicare & Medicaid Services. Decision memo for screening for colorectal cancer – blood-based biomarker tests (CAG-00454N). National Coverage Analysis. [Internet]. 2021. [cited 2025 April 16]. Available from: https://www.cms. gov/medicare-coverage-database/view/ncacal-decision-memo. aspx?NCAId=299
DOI: https://doi.org/10.2478/abm-2025-0029 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Language: English
Page range: 266 - 280
Published on: Oct 31, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2025 Hans Ezekiel T. Olorosisimo, Charlemagne G. Sumperos, Aeryll Lesley A. Adviento, Angel Ann T. Lachica, John Louie A. Cabalteja, An Gheline R. Ubiña, Josiah T. Valentin, Pamela Rose Bremner, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.